To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

ClinicalTrials.gov ID: NCT01768572

Public ClinicalTrials.gov record NCT01768572. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF Antagonists

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Primary Objective: To assess, in the same study, the safety of sarilumab and tocilizumab in participants with rheumatoid arthritis (RA) who were inadequate responders to or intolerant of tumor necrosis factor (TNF) antagonists.

Study identification

NCT ID: NCT01768572
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Sanofi; Industry
Enrollment: 202 participants

Conditions and interventions

Conditions

Rheumatoid Arthritis

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 28, 2013
Primary completion: Sep 30, 2014
Completion: Sep 30, 2014
Last update posted: Jun 25, 2017

2013 – 2014

United States locations

U.S. sites: 14
U.S. states: 8
U.S. cities: 13

Facility	City	State	ZIP	Site status
Investigational Site Number 840152	Huntsville	Alabama	35801	—
Investigational Site Number 840151	Colorado Springs	Colorado	80903	—
Investigational Site Number 840153	Aventura	Florida	33180	—
Investigational Site Number 840033	Fort Lauderdale	Florida	33334	—
Investigational Site Number 840048	Miami	Florida	33155	—
Investigational Site Number 840155	Palm Harbor	Florida	34684	—
Investigational Site Number 840013	Wheaton	Maryland	20902	—
Investigational Site Number 840154	Boston	Massachusetts	02115	—
Investigational Site Number 840150	Lansing	Michigan	48910	—
Investigational Site Number 840062	Reading	Pennsylvania	19611	—
Investigational Site Number 840038	Austin	Texas	78705	—
Investigational Site Number 840022	Dallas	Texas	75235	—
Investigational Site Number 840156	Dallas	Texas	75246	—
Investigational Site Number 840074	Mesquite	Texas	75150	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01768572, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 25, 2017 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01768572 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →